Uneasy alliance—clinical investigators and the pharmaceutical industry

Cited by (641)

Items 101–200 of 641

1. Trust us to make a difference: ensuring public confidence in the integrity of clinical research.
   J. J. Cohen · 2001 · Academic medicine : journal of the Association of American Medical Colleges
2. The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem
   Amy C. Brodkey · 2005 · Academic Psychiatry
3. The 'pinking' of Viagra culture: drug industry efforts to create and repackage sex drugs for women.
   Hartley, Heather · 2006 · Sexualities
4. Overcoming the funding challenge: the cost of randomized controlled trials in the next decade.
   B. Shore, Adam Nasreddine, M. Kocher · 2012 · Journal of Bone and Joint Surgery. American volume
5. Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene
   T. Lemmens · 2004 · Journal of Law, Medicine & Ethics
6. Gendering the migraine market: do representations of illness matter?
   Joanna Kempner · 2006 · Social Science & Medicine (1967)
7. Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators
   K. Weinfurt, Joëlle Y. Friedman, M. Dinan, Jennifer S. Allsbrook, M. Hall, J. K. Dhillon, J. Sugarman · 2006 · Journal of Law, Medicine & Ethics
8. Evidence-based mental health policy: Acritical appraisal
   Boris OGUIBENINE · 2003 · British Journal of Psychiatry
9. Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform
   M. Rodwin · 2012 · Journal of Law, Medicine & Ethics
10. Student Teachers as Advocates for Student-Led Research-Informed Socioscientific Activism
    Larry Bencze, Erin Sperling · 2012 · Canadian Journal of Science Mathematics and Technology Education
11. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy
    Claudia Mehler‐Wex, Michael G. Kölch, Julia Kirchheiner, Gisela Antony, Jörg Michael Fegert, Manfred Gerlach · 2009 · Child and Adolescent Psychiatry and Mental Health
12. Effects of Disclosing Financial Interests on Attitudes Toward Clinical Research
    K. Weinfurt, M. Hall, M. Dinan, Venita Depuy, Joëlle Y. Friedman, Jennifer S. Allsbrook, J. Sugarman · 2008 · Journal of general internal medicine
13. Prevalence and Outcomes of Pharmaceutical Industry—Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine
    R. Procyshyn, A. Chau, P. Fortin, Willough Jenkins · 2004 · Canadian journal of psychiatry. Revue canadienne de psychiatrie
14. A pesquisa clínica no Brasil
    M. Zago · 2004
15. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration
    Benedetto Vitiello, John H. Heiligenstein, Mark A. Riddle, Laurence Lee Greenhill, Jörg Michael Fegert · 2004 · Biological Psychiatry
16. Private Profit, Science, and Science Education: Critical Problems and Possibilities for Action
    J. Bencze · 2008 · Canadian Journal of Science Mathematics and Technology Education
17. Health economists meet the fourth tempter: drug dependency and scientific discourse.
    Steve Morgan, M. Barer, Robert G. Evans · 2000 · Health Economics
18. Association Between Research Sponsorship and Study Outcome in Plastic Surgery Literature
    A. Momeni, A. Becker, H. Bannasch, G. Antes, A. Blümle, G. B. Stark · 2009 · Annals of Plastic Surgery
19. TWO FUNDAMENTAL PROBLEMS IN GERIATRIC MEDICINE
    Gurkirpal Singh, Simu K. Thomas, S. Arcona, V. Lingala, A. Mithal · 2005 · Journal of The American Geriatrics Society
20. Disclosure of financial competing interests in randomised controlled trials: cross sectional review
    C. Gross, Anjali Gupta, H. Krumholz · 2003 · British medical journal
21. Quality of care: the need for medical, contextual and policy evidence in primary care.
    M. van Driel, A. de Sutter, T. Christiaens, J. De Maeseneer · 2005 · Journal of Evaluation In Clinical Practice
22. The proliferation of clinical practice guidelines: professional development or medicine-by-numbers?
    S. Genuis · 2005 · The Journal of the American Board of Family Practice
23. Research ethics II: Mentoring, collaboration, peer review, and data management and ownership.
    J. Horner, F. Minifie · 2011 · Journal of Speech, Language and Hearing Research
24. Shifts in Guidelines for Ethical Scientific Conduct
    K. Montgomery, Amalya L. Oliver · 2009 · Social Studies of Science
25. Viewpoint: the elephant in medical professionalism's kitchen.
    F. Hafferty · 2006 · Academic medicine : journal of the Association of American Medical Colleges
26. The Limits of Disclosure: What Research Subjects Want to Know about Investigator Financial Interests
    C. Grady, E. Horstmann, Jeffrey S. Sussman, S. Hull · 2006 · Journal of Law, Medicine & Ethics
27. Exploring the continuum: medical information to effective clinical practice. Paper I: the translation of knowledge into clinical practice.
    S. Genuis, S. Genuis · 2006 · Journal of Evaluation In Clinical Practice
28. Fat Is a Social Justice Issue, Too
    L. Stoll · 2019 · Humanity and Society
29. Industry-sponsored research.
    Kanu Okike, M. Kocher, C. Mehlman, M. Bhandari · 2008 · Injury
30. Running an ethical trial 60 years after the Nuremberg Code.
    Jonathan Markman, M. Markman · 2007 · The Lancet Oncology
31. Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
    M. Hartmann, H. Knoth, D. Schulz, S. Knoth · 2003 · British Journal of Cancer
32. The Human Subjects Trade: Ethical and Legal Issues Surrounding Recruitment Incentives
    T. Lemmens, Paul B. Miller · 2003 · Journal of Law, Medicine & Ethics
33. From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study.
    J. Z. Zwart-van Rijkom, F. Broekmans, H. Leufkens · 2002 · Human Reproduction
34. Rhetoric and Hype
    B. Williams-Jones, Oonagh P. Corrigan · 2003 · American Journal of Pharmacogenomics
35. The effect of ad hominem attacks on the evaluation of claims promoted by scientists
    Ralph M. Barnes, Heather Moynihan Johnston, Noah MacKenzie, Stephanie J. Tobin, Chelsea M. Taglang · 2018 · PLoS ONE
36. Should Society Allow Research Ethics Boards to Be Run As For-Profit Enterprises?
    E. Emanuel, T. Lemmens, C. Elliot · 2006 · PLoS Medicine
37. Restoring and Preserving Trust in Biomedical Research
    M. Yarborough, R. Sharp · 2002 · Academic medicine : journal of the Association of American Medical Colleges
38. The research subject as wage earner
    James A. Anderson, C. Weijer · 2002 · Theoretical Medicine and Bioethics
39. United States Private-Sector Physicians and Pharmaceutical Contract Research: A Qualitative Study
    J. Fisher, C. Kalbaugh · 2012 · PLoS Medicine
40. Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.
    Susannah L. Rose, M. Krzyzanowska, S. Joffe · 2010 · Journal of Clinical Oncology
41. Ethics and The Pharmaceutical Industry
    S. Green · 2008 · Australasian Psychiatry
42. Embedded Science: Critical Analysis of Abstinence-Only Evaluation Research
    S. McClelland, M. Fine · 2008 · Culture Studies &#x2194 Critical Methodologies
43. Does Industry Sponsorship Undermine the Integrity of Nutrition Research?
    Mira Katan · 2006 · PLoS Medicine
44. Ethical assessment of industry-sponsored clinical trials: a case analysis.
    F. Miller, A. Shorr · 2002 · Chest
45. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies--part II--study design, outcome measures, data analysis, and reporting.
    C. Mcmahon · 2008 · Journal of Sexual Medicine
46. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
    S. Gray, F. Hlubocky, M. Ratain, C. Daugherty · 2007 · Journal of Clinical Oncology
47. When Labels Mask Oppression: Implications for Teaching Psychiatric Taxonomy to Mental Health Counselors
    Lisa Cosgrove · 2005 · Journal of Mental Health Counseling
48. What do we really know about conflicts of interest in biomedical research?
    T. Warner, J. P. Gluck · 2003 · Psychopharmacology
49. Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials
    Kasenda, Benjamin, von Elm, Erik, You, John J., Blümle, Anette, Tomonaga, Yuki, Saccilotto, Ramon, Amstutz, Alain, Bengough, Theresa, Meerpohl, Joerg J., Stegert, Mihaela et al. · 2016 · PLOS Medicine
50. Impact of industry collaboration on randomized controlled trials in oncology
    Anne S. Linker, An-Nie Yang, N. Roper, Evans Whitaker, D. Korenstein · 2016 · European Journal of Cancer
51. The Protectors and the Protected: What Regulators and Researchers Can Learn from IRB Members and Subjects
    A. F. Cook, H. Hoas, J. C. Joyner · 2013 · Narrative Inquiry in Bioethics
52. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case.
    M. Waldinger, D. Schweitzer · 2008 · Journal of Sexual Medicine
53. Evidence-Based Medicine: Watching Out for Its Friends
    H. Brody, F. Miller, Elizabeth Bogdan-Lovis · 2005 · Perspectives in biology and medicine
54. Science, bioethics, and the public interest: on the need for transparency.
    V. Sharpe · 2002 · The Hastings center report
55. Preliminary Report on the Use of High-Fidelity Simulation in the Training of Study Coordinators Conducting a Clinical Research Protocol
    Jeffrey M. Taekman, Gene W. Hobbs, Linda Barber, B. Phillips-bute, Melanie C. Wright, M. Newman, M. Stafford-Smith · 2004 · Anesthesia and Analgesia
56. Research on the Drug Treatment of Schizophrenia
    D. Cohen · 2002 · Journal of Social Work Education
57. In favour of a Millian proposal to reform biomedical research
    Julian Reiss · 2010 · Synthese
58. A turning point for conflicts of interest: the controversy over the National Academy of Sciences' first conflicts of interest disclosure policy.
    M. Parascandola · 2007 · Journal of Clinical Oncology
59. The EU-regulation on medicinal products for paediatric use
    M. Kölch, Kathlen Schnoor, J. Fegert · 2007 · European Child and Adolescent Psychiatry
60. Behavior Analysis of Psychotic Disorders: Scientific Dead End or Casualty of the Mental Health Political Economy?
    S. E. Wong · 2006 · Behavior and Social Issues
61. The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures.
    Melanie C. Wright, Jeffrey M. Taekman, Linda Barber, Gene W. Hobbs, M. Newman, M. Stafford-Smith · 2005 · Contemporary Clinical Trials
62. Financial Conflicts of Interest in Human Subjects Research: The Problem of Institutional Conflicts
    Mark Barnes, Patrik S. Florencio · 2002 · Journal of Law, Medicine & Ethics
63. The clinical trial: deceitful, disputable, unbelievable, unhelpful, and shameful--what next?
    Richard Horton · 2001 · Controlled Clinical Trials
64. Consent document translation expense hinders inclusive clinical trial enrolment
    Maria A. Velez, Beth A. Glenn, Maria De Lourdes Garcia-Jimenez, Amy Lauren Cummings, Aaron Elliott Lisberg, Andrea Nañez, Yazeed Radwan, Jackson P Lind-Lebuffe, Paige M Brodrick, Debory Li et al. · 2023 · Nature
65. When Health Policy Is the Problem: A Report from the Field
    Spitz, Bruce, Abramson, John · 2005 · Journal of Health Politics, Policy and Law
66. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study
    Tanvee Varma, Michelle M. Mello, Joseph S. Ross, C. Gross, Jennifer Miller · 2023 · BMJ Medicine
67. The pharmaceutical corporation and the 'good work' of managing women's bodies.
    Tasleem J. Padamsee · 2011 · Social Science & Medicine (1967)
68. Simulation for clinical research trials: A theoretical outline
    Peter George Brindley, William F. Dunn · 2009 · Journal of Critical Care
69. Children in Clinical Research: A Conflict of Moral Values
    Vera Hassner Sharav · 2003 · The American Journal of Bioethics
70. Bioterrorism and Patent Rights: "Compulsory Licensure" and the Case of Cipro
    D. Resnik, K. D. De Ville · 2002 · American Journal of Bioethics
71. Conflicts of interest in dermatology.
    H. Williams, L. Naldi, C. Paul, A. Vahlquist, S. Schroter, R. Jobling · 2006 · Acta Dermato-Venereologica
72. Primary care physicians' views about gatekeeping in clinical research recruitment: A qualitative study
    M. Guillemin, Rosalind J. McDougall, Dominique E. Martin, N. Hallowell, Alison Brookes, L. Gillam · 2017 · AJOB Empirical Bioethics
73. Independent clinical research in Europe.
    G. Remuzzi, A. Schieppati, J. Boissel, S. Garattini, R. Horton · 2004 · The Lancet
74. Patenting the sun: Enclosing the scientific commons and transforming the university—ethical concerns
    D. Triggle · 2004 · Drug Development Research
75. Publication of clinical trials: accountability and accessibility
    Marea B. Tumber, Kay Dickersin · 2004 · Journal of Internal Medicine
76. Legal issues in scientific research.
    P. Kalb, K. Koehler · 2002 · Journal of the American Medical Association (JAMA)
77. Editorial bias in scientific publications
    Jorge Matías‐Guiu, R. García-Ramos · 2011 · Neurología (English Edition)
78. Individual Differences in Cognitive Style, Learning Style and Instructional Preference in Medical Education
    L. Curry · 2002 · Springer international handbooks of education
79. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research
    J. M. de la Torre Hernández, E. Edelman · 2017 · Revista Española de Cardiología
80. Development and Successful Application of a “Community-First” Communication Model for Community-Based Environmental Health Research
    E. Emmett, Hong Zhang, F. Shofer, N. Rodway, Chintan Desai, David Freeman, M. Hufford · 2009 · Journal of Occupational and Environmental Medicine
81. Issues that May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effect
    John M. Davis, N. Chen, I. Glick · 2008 · Neuropsychopharmacology
82. The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration.
    J. Bassand, John D. Martin, L. Rydén, M. Simoons · 2002 · The Lancet
83. Maintaining the integrity of the scientific record
    Richard Smith · 2001 · British medical journal
84. Cervical disc arthroplasty: do conflicts of interest influence the outcome of clinical studies?
    Ankur S. Narain, Fady Y. Hijji, Kelly H. Yom, Krishna T. Kudaravalli, Kern Singh · 2017 · The spine journal
85. Blowback
    E. House · 2008 · American Journal of Evaluation
86. Enabling TRIPs: The pharma–biotech–university patent coalition
    D. Tyfield · 2008
87. Ethical attitudes of nurse, physician, and unaffiliated members of institutional review boards.
    W. Rothstein, Linh Phương · 2007 · Journal of Nursing Scholarship
88. Ethical issues in psychopharmacology
    L. McHenry · 2006 · Journal of Medical Ethics
89. Changes in the American Interventional Radiology Literature: Comparison over a 10-Year Time Period
    Charles E. Jr Ray, Rajan K. Gupta, J. Blackwell · 2006 · Cardiovascular and Interventional Radiology
90. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry.
    D. Henry, E. Doran, I. Kerridge, S. Hill, P. McNeill, R. Day · 2005 · Archives of Internal Medicine
91. Viewpoint:: Professional Integrity in Industry-Sponsored Clinical Trials
    F. Miller, H. Brody · 2005 · Academic medicine : journal of the Association of American Medical Colleges
92. Research Accountability and Financial Conflicts of Interest in Industry Sponsored Clinical Research: A Review
    Patricia M. Tereskerz · 2003 · Accountability in Research
93. Ética de la prescripción. Conflictos del médico con el paciente, la entidad gestora y la industria farmacéutica
    S. Moreno · 2001 · Medicina Clínica
94. Ethics and EBM: acknowledging bias, accepting difference and embracing politics.
    I. Kerridge · 2010 · Journal of Evaluation In Clinical Practice
95. Corporate funding and conflicts of interest: a primer for psychologists.
    W. Pachter, R. Fox, P. Zimbardo, D. Antonuccio · 2007 · American Psychologist
96. Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study
    C. Snowdon, D. Elbourne, Jo Garcia, M. Campbell, V. Entwistle, David Francis, A. Grant, Rosemary C. Knight, A. McDonald, I. Roberts · 2006 · Trials
97. Hormones, menopause, and heart disease: Making sense of the Women’s Health Initiative
    Paula S. Derry · 2004 · Women s Health Issues
98. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    J. Tuech, G. Moutel, P. Pessaux, V. Thoma, S. Schraub, C. Hervé · 2005 · European Journal of Cancer
99. Ethical considerations in psychopharmacological research involving decisionally impaired subjects
    D. Rosenstein, F. Miller · 2003 · Psychopharmacology
100. Tobacco harm reduction: a call to address the ethical dilemmas.
     B. J. Fox, Joanna E. Cohen · 2002 · Nicotine & Tobacco Research